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ABSTRACT
2020 will be remembered worldwide for the outbreak of Coronavirus disease (COVID-19), which
quickly spread until it was declared as a global pandemic. The main protease (Mpro) of SARS-CoV-2, a
key enzyme in coronavirus, represents an attractive pharmacological target for inhibition of SARS-CoV-
2 replication. Here, we evaluated whether the anti-inflammatory drug Ibuprofen, may act as a poten-
tial SARS-CoV-2 Mpro inhibitor, using an in silico study. From molecular dynamics (MD) simulations, we
also evaluated the influence of ionic strength on the affinity and stability of the Ibuprofen–Mpro com-
plexes. The docking analysis shows that R()Ibuprofen and S(þ)Ibuprofen isomers can interact with
multiple key residues of the main protease, through hydrophobic interactions and hydrogen bonds,
with favourable binding energies (6.2 and 5.7 kcal/mol, respectively). MM-GBSA and MM-PBSA cal-
culations confirm the affinity of these complexes, in terms of binding energies. It also demonstrates
that the ionic strength modifies significantly their binding affinities. Different structural parameters cal-
culated from the MD simulations (120 ns) reveal that these complexes are conformational stable in the
different conditions analysed. In this context, the results suggest that the condition 2 (0.25 NaCl) bind
more tightly the Ibuprofen to Mpro than the others conditions. From the frustration analysis, we could
characterize two important regions (Cys44-Pro52 and Linker loop) of this protein involved in the inter-
action with Ibuprofen. In conclusion, our findings allow us to propose that racemic mixtures of the
Ibuprofen enantiomers might be a potential treatment option against SARS-CoV-2 Mpro. However, fur-
ther research is necessary to determinate their possible medicinal use.
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In late 2019, a novel coronavirus was identified as the cause
of an outbreak of pneumonia cases in Wuhan, the largest
city in China’s central region. In February 2020, the World
Health Organization (WHO) designated the disease COVID-19,
which stands for coronavirus disease 2019 (Rodrıguez-
Morales et al., 2020; World Health Organization et al., 2020),
which quickly spread to several countries until it became a
global pandemic. The virus that causes COVID-19 is desig-
nated severe acute respiratory syndrome-coronavirus 2
(SARS-CoV-2); as the RNA genome is similar to the SARS cor-
onavirus (SARS-CoV). Considering that there is currently only
one non-specific antiviral drug (Remdesivir) approved by the
FDA for the treatment of certain adult and pediatric patients
with COVID-19 (Food and Drug Administration, 2020), one of
the biggest challenges in global therapeutic is to develop
potent antiviral agents capable of inhibiting the COVID-19
virus, in the shortest possible time. In this direction, one of
the best characterized pharmacological targets of this virus is
the main protease (Mpro) of SARS-CoV-2, also known as 3-
chymotrypsin-like protease (3CLpro) (Jin et al., 2020).
It is characterized by its great similarity with the SARS-
CoV Mpro (published in 2003). These proteins are homolo-
gous and they have high levels of sequence similarity;
however, shown differences in the active site in size and
shape, indicating that designing drugs based on SARS-CoV
might not be effective (Bzowka et al., 2020). Along with
papain-like protease, this enzyme is essential for processing
polyproteins, into which the viral RNA is initially translated
after it has entered the human cells. The SARS-CoV-2 Mpro
protease cleaves at no less than 11 conserved sites on the
large polyprotein 1ab (replicase 1ab, 790 kDa) (Boopathi
et al., 2020; Gao et al., 2020; Mirza & Froeyen, 2020).
Their structure is a homodimer in which the two subunits
are arranged perpendicular to each other. Each subunit has
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3 structural domains; between domain I and II lies the sub-
strate binding site, comprising the residues that make up the
catalytic dyad (His41 and Cys145). A long loop region (resi-
dues 185–200) connects catalytic domains with the domain
III. The domain III (residues 201–303) is involved in the
dimerization process of the protein, being crucial for the
activity of the enzyme (Zhang et al., 2020). Inhibiting their
activity would block viral replication. Since its discovery, this
protease has been the motivation of several publications
intended to understand its mechanism of action and the
design of possible inhibitors (Estrada, 2020; Gentile et al.,
2020; Macchiagodena et al., 2020).
In silico methods using computational approaches are
extremely useful tools for evaluating ligand–protein interac-
tions during the drug discovery process. They facilitate the
identification of molecules capable to modulate the bio-
logical activity of the protein, providing scientific information
on candidate drugs for the treatment of this viral infection.
To date, there are numerous publications focused on the vir-
tual screening of potential SARS-CoV-2 Mpro inhibitors on
the basis of natural or synthetic compounds from different
databases or libraries (Adem et al., 2020; Fischer et al., 2020;
Gentile et al., 2020; Omar et al., 2020; Ton et al., 2020; Wu
et al., 2020), and also from clinically approved drugs for
other diseases (Kandeel & Al-Nazawi, 2020; Kumar
et al., 2020).
Particularly, in an emergency like this, repurposing of
FDA-approved drugs for other diseases represents a very
good option, to speed up clinical trials. Most of these drugs
have sufficient experience and dosage, and their safety is
well known. Once efficacy is validated, these can be
approved by health authorities and the hospital’s ethics com-
mittee for the rapid clinical treatment of patients. In recent
times, compounds currently used for the treatment of non-
infectious diseases as potential antimicrobial alternatives
have also been reviewed (Lagadinou et al., 2020;
Zimmermann & Curtis, 2017). One example is Ibuprofen, a
nonsteroidal anti-inflammatory drug (NSAID) widely used for
relief of pain, fever and inflammation, which has demon-
strated novel pharmacological actions against bacteria (Dai
et al., 2019; Obad et al., 2015; Shah et al., 2018), fungi
(Ogundeji et al., 2016; Sanyal et al., 1993) and viruses (Pan
et al., 2018; Veljkovic et al., 2015). Interestingly, a short time
ago, it was reported a nebulizable formulation of sodium
Ibuprofen in high ionic strength with bactericidal properties
for the treatment of respiratory infections of fibrotic patients
(Mu~noz et al., 2018). In addition to exhibiting antiviral prop-
erties. The authors of the work highlight that the presence
of sodium chloride (NaCl) in the formulation, a condition nor-
mally used in a nebulizable solution to fluidize and facilitate
the elimination of mucus from the lungs, improves the bac-
tericidal activity of the amphipathic molecule of Ibuprofen
soluble, obtaining an effect bactericidal at very low concen-
trations of Ibuprofen and, in particular, at short periods of
time. This phenomenon would be related to the influence of
ionic strength on the surface properties of this amphipathic
Ibuprofen, since they observe that high concentrations of
salts favour the approach and insertion of this compound
into the membrane, triggering changes in electrical conduct-
ivity and its resulting instability. Besides, this Ibuprofen inhal-
ation does not seem to produce substantial changes in the
general state of the animals or significant histopathological
alterations in the organs analysed. On the other hand,
recently a report suggests that Ibuprofen might impact
SARS-CoV-2 induced disease by indirect interaction with actin
protein (Veljkovic et al., 2020).
Based on the evidence mentioned, in this work, we pro-
posed to evaluate the binding affinity and identify the
ligand–protein interactions of Ibuprofen enantiomers (FDA
approved drug with excellent safety record) with the Mpro
of SARS-CoV-2 in different simulated environments, using a
molecular docking and molecular dynamic (MD) simulations
studies. Also, we calculated different structural parameters
from trajectories generated by the simulations to explore the
dynamic behaviour and the stability of the Ibuprofen–Mpro
complexes in the selected environments.
The purpose of this study is to investigate whether
Ibuprofen could be useful in the treatment of COVID-19 by
direct interaction with SARS-CoV-2 Mpro.
Materials and methods
Preparation of ligands
Considering that the majority of the approved pharmaceut-
ical forms of Ibuprofen consist of racemic mixtures of the
R() and S(þ) enantiomers, but it is proven that the S(þ)
enantiomer is the pharmacologically active (Adams et al.,
1976; Evans, 2001), both were analysed separately. The 2D
structures of R()Ibuprofen and S(þ)Ibuprofen enantiomers
(Figure 1) were downloaded from PubChem (https://pub-
chem.ncbi.nlm.nih.gov) in SDF format and then converted to
PDB format using the Open Babel (O’Boyle et al., 2011) soft-
ware. Hydrogen atoms were added to the ligands, the
energy was minimised and converted to pdbqt format using
the MGL tools of the AutoDockTools4 software (Trott &
Olson, 2010) for further analysis.
Figure 1. 2D representation of Ibuprofen enantiomers.
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Preparation of protein
Three-dimensional structure of SARS-CoV-2 Mpro (PdbId:
6Y84) with resolution 1.39 Å was collected from Protein Data
Bank (PDB, 1971, http://www.rcsb.org/). The crystallized struc-
ture of the monomer of SARS-CoV-2 Mpro (Owen et al.,
2020) was used for the docking molecular and MD simula-
tions, based on references indicating that only one monomer
is active in the SARS-CoV-2 Mpro homodimer (Chen et al.,
2006). All the molecules that are not part of the structure of
the protein were removed. Hydrogen atoms were added to
the proteins and converted to pdbqt format using the MGL
tools of the AutoDockTools4 software (Trott & Olson, 2010)
for later analysis.
Molecular docking
In order to select the preferred orientation of the enantiom-
ers with the protein to form a stable complex, we docked
both enantiomers within the active site of the chain A of the
three-dimensional structure of SARS-CoV-2 Mpro (PdbId:
6Y84) using Autodock Vina (Trott & Olson, 2010). The pos-
ition of the catalytic residues for the Mpro structure was
obtained from bibliography (Das et al., 2020; Estrada, 2020;
Gentile et al., 2020; Zhang et al., 2020). The box size
remained the same for all runs: 30 30 30Å. The docked
complexes with the most favourable binding modes were
selected for molecular dynamics simulations.
The analysis of the 2D interactions of the ligand–protein
complexes were analysed with LigPlotþprogram (Laskowski
& Swindells, 2011) and for the 3D visualization PyMol (LLC
Schrodinger, 2008) was used.
Molecular dynamic simulations
It is known that the ionic strength determines the protein
folding in solution (Gabrielczyk et al., 2017) and influences
on the ligand–protein binding affinity (Papaneophytou et al.,
2014). As mentioned above, there are evidences of benefits
attributed to the inhalation of a hypertonic saline solution
(HTS) in the treatment of patients with lung diseases. It has
even been described beneficial effects on the bactericidal
activity of ibuprofen against agents involved in the develop-
ment of lung pathologies (Mu~noz et al., 2018). Thus, we per-
formed MD simulations to evaluate the influence of ionic
strength (NaCl concentration) on the structure of the
Ibuprofen–Mpro complexes.
In order to analyse the dynamics of the complexes in dif-
ferent concentrations of NaCl, four different environments
were simulated for each complex. Condition 1: only
Naþ ions to neutralize the complex, condition 2: 0.25M
NaCl, condition 3: 0.50M NaCl and condition 4: 1M NaCl. An
accurate rule (Machado & Pantano, 2020) was used to define
the electrolytic content in simulation boxes and obtain the
expected models with NaCl concentrations in the system
(0.25M, 0.5M and 1M).
All MD simulations were run using the AMBER20 software
package (Case et al., 2020) with the protein being assigned
ff99SB (Hornak et al., 2006) parameters and docked ligands
being assigned GAFF (Wang et al., 2004) parameters aug-
mented by AM1-BCC (Jakalian et al., 2000, 2002) partial
charges. Solvation of the systems were carried out using the
TIP3P (Jorgensen et al., 1983) explicit water model and the
AMBER pmemd module was used to perform energy minimi-
zations and MD.
A two-stage solvent energy minimization was performed.
In the first stage, an energy minimization was performed in
order to relax the solvation structure, thus restricting the
protein atoms leaving it fixed in order to allow the solvent in
the solvent box to move and relax around the protein, this
stage consisted of 2.000 steps. In the second step, another
minimization of the energy of the solvent was performed
but without any restrictions to obtain the optimization of
the geometry of the whole system (protein and solvent), this
process consisted of 8.000 steps. Then, the thermalization of
the system was performed according to the AMBER force
field, the system was heated from 0K to 298 K gradually. A
temperature ramp was generated for this purpose, which
was increased until the expected temperature was achieved,
using the SHAKE (Van Gunsteren & Berendsen, 1977) algo-
rithm in 10.000 steps. After heating, an equilibration for
20 ns was attained at constant temperature and pressure
(298 K and 1 Bar) to accommodate the system volume to
obtain an adequate density.
Finally, the well-equilibrated complexes were then subject
to the production phase without any restrains for a period of
120 ns with a time step of 2fs, and after every 2 ps the struc-
tural coordinates were saved. The CPPTRAJ module (Roe &
Cheatham, 2013) of Amber tool was used to calculate the
root mean square deviation (RMSD), root mean square fluctu-
ation (RMSF) and to analyse the hydrogen bonds from the
trajectories generated by the simulations. All the analysis of
the 2D interactions of the ligand–protein complexes was
using LigPlotþ program (Laskowski & Swindells, 2011) and
for the 3D visualization was PyMol (LLC Schrodinger, 2008).
MM-GBSA and MM-PBSA binding free
energies estimation
Both Molecular Mechanics-Generalized Born Surface Area
(MM-GBSA) and Molecular Mechanics-Poisson Boltzmann sur-
face area (MM-PBSA) analyses were carried out by using the
MMPBSA.py (Miller et al., 2012) python script implemented in
the AMBER20 package with the aim to estimate the binding
free energy of ibuprofen enantiomers with SARS-CoV-2 Mpro.
The binding free energies (reported in kcal/mol) in MM-
PBSA method and its complementary MM-GBSA method cal-
culate the difference between bound and unbound state of
solvated conformations of a molecule (Equation (1))
DGbind, solv ¼ DGbind, vacuum þ D Gsolv, complex
 D Gsolv, ligand þ D Gsolv, receptor
 
(1)
The energy terms were extracted every 20 ns of each
respective MD trajectory (120 ns) by selecting 1000 uniformly
spaced out snapshots. The salt concentration (saltcon) in
Generalized Born and the ionic strength (istrng) in Poisson
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Boltzmann were modified according to the different saline
environments of the simulations.
Structural analysis
For localizing frustration in all pdb files extracted from the MD
simulations the frustratometer tool (Jenik et al., 2012; Parra
et al., 2016) (http://www.frustratometer.tk/) was used. There are
three ways to calculate frustration, two of them are at contact
level frustration. In this case, the frustration is calculated
between residues in contact in the protein structure and are
called mutational and configurational. The third way is at single
level frustration that calculate frustration per residue. The frus-
tration index (FI) can be classified into three classes, highly frus-
trated (FI  1, residues or contacts that are in conflict with
the structures), minimally frustrated (FI  0.78, residues or con-
tacts that are important for protein stability) and neutral
(1< FI < 0.78, this residues or contact are neutral in structure
stability) (Jenik et al., 2012; Parra et al., 2016). The expected val-
ues of highly frustrated contacts or residues are 10% for minim-
ally frustrated residues is 50% and for neutral is 40% (Ferreiro
et al., 2007). In this study, the configurational FI and the single
level frustration were used.
Results and discussions
Docking molecular
The enantiomers of Ibuprofen were individually docked into
the crystal structure of SARS-CoV-2 Mpro (PdbId: 6Y84). The
docking analysis of both enantiomers generated negative
values for free energy with the SARS-CoV-2 protease, sug-
gesting a favourable binding affinity for this protein. It stands
out that R()Ibuprofen (6.2 kcal/mol) bound to Mpro with
a DG value lower than S(þ)Ibuprofen (5.7 kcal/mol).
The Ibuprofen–Mpro interactions were analysed and the
results contrasted with bibliography in terms of key residues
involved in catalytic activity, substrate binding and dimeriza-
tion process of SARS-CoV-2 Mpro (Estrada, 2020; Gao et al.,
2020; Macchiagodena et al., 2020; Zhang et al., 2020).
Figure 2 shown the best affinity poses and the interac-
tions of both enantiomers with the SARS-CoV-2 Mpro.
According to the results obtained, both enantiomers fully fit
within the active site of Mpro (Figure 2(A)) and interact with
multiple key residues, establishing hydrophobic contacts
with all the molecule and electrostatic bond through the
carboxyl group (Figure 2(B,C)).
Upon examining the molecular interactions, it can be
seen that both isomers (Figure 2(B,C)) were found to be
interacting with catalytic residues (His41-Cys145), the sub-
strate-binding pocket and interacting with residues involved
in dimerization process (Phe140 and Glu166). We highlight
the fact that the enantiomers interacted differentiated with
the residues of the catalytic dyad. This finding is significant
considering that most of the approved pharmaceutical forms
of this drug consist of racemic mixtures of its enantiomers
R() and S(þ).
In addition, both enantiomers interacted with the Glu166
residue. Key residue that plays a connecting role between
the substrate binding site and the dimer interface, necessary
for enzymatic activity.
On the other hand, the individual analysis of molecular
interactions suggests that the S(þ)Ibuprofen may have its
own favourable binding with the S1 subsite, a structural fea-
ture essential for catalysis. It interacts with Gly143, Ser144
and Cys145 in S1 pocket (Figure 2(C)), an operational elem-
ent called the “oxyanion hole” (Zhang et al., 2020). This
pocket typically consists of backbone amides or positively
charged residues, crucial to stabilize the tetrahedral inter-
mediate produced during proteolysis (Su et al., 2020).
Moreover, S(þ)Ibuprofen interacts with aminoacids impli-
cated in dimerization process (Phe140 and Glu166), position-
ing it also as a possible candidate to inhibit dimer formation,
as mentioned above. Similar results have been described in
detail for promising Mpro inhibitors (Ghosh et al., 2020).
It is important to point out that it was found that R(-
)Ibuprofen interacts with residues of the Linker loop region
(185–200) that links the domain (Iþ II) with domain III, a
region that is being studied for its fundamental role in the
control of dimerization and enzymatic activity (Bzowka et al.,
2020; Menendez et al., 2020). Therefore, this interaction with
these residues could be significant for the activity.
Considering that the static pose of the ligand–protein com-
plexes obtained by molecular docking do not provide informa-
tion that represents and characterizes the stability of each
complex, both complexes were subjected to molecular dynam-
ics simulations accompanied by calculations of various parame-
ters to examine the real movement and structural modifications
that undergo in the different selected conditions.
Molecular Dynamic simulations
As described above, MD simulation studies of 120 ns for each
complex, in four different environments were carried out.
The trajectories obtained for simulations run were analysed
using RMSD, RMSF, ligand–protein binding contacts in terms
of hydrogen bonding and binding free energy calculations
(MM-GBSA and MM-PBSA).
RMSD is a useful parameter to quantify the overall struc-
tural stability of a ligand–protein complex after binding of
ligand within the active site of protein, in function of a
period of time. It can be seen in the RMSD graphs (Figure 3)
that the two complexes analysed show deviations within the
RMSD range of 1.0 Å to 3.5 Å during the simulations. Values
up 3–4Å are wholly satisfactory for globular proteins, indicat-
ing that their bindings are significant stable in all the ana-
lysed systems.
The average RMSD values of simulated complexes for
R()Ibuprofen–Mpro and S(þ)Ibuprofen–Mpro in condition 1
were 2.15 Å and 2.46 Å, in condition 2 were 1.86 Å and
2.05 Å, in condition 3 were 2.00 Å and 2.65 Å, in condition 4
were 1.78 Å and 2.04 Å, respectively. Based on these average
RMSD values, we can clearly infer that the Ibuprofen–Mpro
complexes are conformational stable, highlighting that the
RMSD value of the R()Ibuprofen–Mpro complex was slightly
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lower than the S(þ)Ibuprofen–Mpro complex in all the condi-
tions analysed.
Respect to the impact of the ionic strength (NaCl concen-
tration) on the ligand–protein stability, the RMSD results indi-
cate that the ionic strength did not significantly influence on
the structural stability of Ibuprofen–Mpro complexes.
However, within this context of overall stability, both com-
plexes in condition 2 (0.25M NaCl) and condition 4 (1M
NaCl) obtained the lowest average RMSD values after 120 ns
of simulation trajectory, suggesting that in these conditions
are slightly more stable than in the other conditions.
Moreover, the RMSF values were calculated in order to
evaluate the fluctuations of each residue of target protein
and the ligand in the complex under the different simulated
conditions (Figure 4). RMSF is a useful parameter to identify
the flexible residues or regions in the protein. The estimated
average RMSF values of protein residues (1–304) in com-
plexes for R()Ibuprofen–Mpro and S(þ)Ibuprofen–Mpro in
Figure 2. Docked poses. A. Molecular surface of SARS-CoV-2 Mpro (PdbId: 6Y84) with R()Ibuprofen (red) and S(þ)Ibuprofen (cyan) enantiomers. 2D visualization
of the interactions visualized by LigPlotþ of B. R()Ibuprofen and C. S(þ)Ibuprofen, H-bond are represented as a dashed line in green and hydrophobic interac-
tions are represented as lines in red.
Figure 3. RMSD of the backbone atoms of the docked complexes. In red R()Ibuprofen–SARS-CoV-2 complex, in black S(þ)Ibuprofen–SARS-CoV-2 complex.
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condition 1 were 1.12 Å and 1.07 Å, in condition 2 were
1.08 Å and 0.95 Å, in condition 3 were 1.09 Å and 1.02 Å, in
condition 4 were 0.97 Å and 1.15 Å, respectively.
As a result, we can infer that the protein residues in the
different simulated environments had a similar fluctuation
profile, with fluctuations within a range of 1–3Å during
whole simulation time. This similarity in the RMSF plots and
average values indicates that the ionic strength did not sig-
nificant effect on the overall flexibility of the protein in all
the simulations. However, it is interesting to note a visible
difference in two regions of the protein under condition 2. In
this condition the residues ranging from 40 to 55 (Loop
Cys44-Pro52) and 180–200 (Linker loop 185–200) fluctuated
less compared to the other conditions, indicating that these
regions have less flexibility. Important fact if we consider
that the conformational variations of these loops might
modifies the dimerization process and enzymatic activity of
the SARS-CoV-2 Mpro.
Additionally, the average RMSF value of R()Ibuprofen
and S(þ)Ibuprofen (305) in complexes with Mpro in condi-
tion 1 were 2.35 Å and 1.23 Å, in condition 2 were 1.01 Å and
0.89 Å, in condition 3 were 1.49 Å and 3.20 Å, in condition 4
were 2.95 Å and 1.67 Å, respectively (Figure 3). From these
data, it can be inferred that their bindings are stable during
the dynamics. These values also indicated that both ligands
undergone relatively less fluctuations under the condition 2.
In order to examine the stability of the ligands in the
Mpro binding pocket, the conformations of the MD simula-
tion were extracted every 20 ns and the interactions were
visualized between the protein and the corresponding
enantiomer (Figure S1 [A–H], supplementary material). Both
enantiomers remained in the binding pocket throughout the
simulation period, forming hydrogen bonds and hydrophobic
interactions. It is observed in docked poses that both enan-
tiomers fully fit within the active site of the SARS-CoV-2
Mpro, in all environments analysed. However, it can be
appreciated different interactions and postures of isomers
within the active site.
Hydrogen bond analysis
Hydrogen bonding is among the most crucial parameters to
understand the binding affinity of candidate ligand towards
a target protein. Analysing the hydrogen bonds during a
simulation clarifies the mode of interaction of the ligand
with the different residues of the protein. A large number of
H-bonds present in between them evidence a strong bind-
ing affinity.
Therefore, we perform an analysis of the number of
hydrogen bonds formed during the simulated trajectories
(Figure 5), as well as the identity of the protein residues and
the atom of the ligand that formed the hydrogen bond.
We can observe that the complex with R()Ibuprofen,
except in condition 4, formed more hydrogen bonds
than S(þ)Ibuprofen.
Besides, analysing the behaviour of the hydrogen bonds
of both enantiomers in the different conditions, it was found
that a greater amount of hydrogen bonds was present in
condition 2 during 120 ns of MD simulation.
Examining the residues of the protein involved in the for-
mation of the hydrogen bonds with the enantiomers in all
simulated trajectories (Figure S2 [A–H], supplementary mater-
ial), it was observed that for the R()Ibuprofen–Mpro com-
plex the residues Gln192 and Thr190 were the residues with
the highest hydrogen bonds formed during the entire simu-
lated trajectories in conditions 1, 2 and 3. Whereas, in condi-
tion 4 they were Asp187 and Gln189. All these residues
comprise the Linker loop (185–200) region.
As for the S(þ)Ibuprofen–Mpro complex, it was seen that
were Gly143 and Glu166 in conditions 1 and 4. In condition
2, they were Thr190 and Gln192, and in condition 3 they
were Gln189 and Thr190.
Figure 4. RMSF of the backbone atoms of the docked complexes. In red R()Ibuprofen–SARS-CoV-2 Mpro complex, in black S(þ)Ibuprofen–SARS-CoV-2
Mpro complex.
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Binding free energies
Both MM-GBSA and MM-PBSA analyses were carried out all
systems to predict their binding affinities (Tables S1–S16,
supplementary material). These energies obtained were aver-
aged and standard deviations were determined.
The calculated DG binding energy for the complex
R()Ibuprofen–SARS-CoV-2 Mpro simulated in the different con-
ditions by MM-GBSA method was found to be 21.5825,
27.0388, 24.3249 and 18.5589, respectively. For MM-PBSA:
21.7934, 26.5194, 22.2433 and 17.3998, respectively. By
comparing the binding free energy, it was found that the
R()Ibuprofen simulated in the condition 2 (0.25M NaCl) bound
more tightly to the SARS-CoV-2 Mpro than the others conditions.
With respect to S(þ)Ibuprofen, the calculated DG binding
energy in the different conditions by MM-GBSA was found to
be 17.1715, 27.1710, 15.0095 and 20.0240, respectively.
For MM-PBSA: 16.9713, 24.6250, 13.7777 and 21.2142,
respectively. Again, it was found that the condition 2 bound
more tightly the Ibuprofen to the SARS-CoV-2 Mpro than the
others conditions.
Both results indicated that the major favourable contribu-
tors were van der Waals (VDWAALS) interactions and electro-
static (EEL) and while the polar component of solvation (DG
polar) contributed unfavourably to the binding of enantiom-
ers. In most conditions, the total binding energy in the MM-
GBSA method was lower compared to the MMPBSA.
In addition, by comparation of the estimated DG values
we can infer that the ionic strength (NaCl concentration)
significantly modifies the binding affinity of Ibuprofen–Mpro
complexes, being condition 2 the most favourable. A direct
correlation can be observed between the number of hydro-
gen bonds and the binding energies calculations in the dif-
ferent conditions analysed.
On the other hand, we can observe that in most of the ana-
lysed conditions the R()Ibuprofen–Mpro complex showed bet-
ter binding free energy than S(þ)Ibuprofen–Mpro. Results that
are in agreement with the DG data obtained from molecular
docking studies and higher number of hydrogen bonds.
Structural analysis
In order to perform a structural analysis of R()Ibuprofen–SARS-
CoV-2 and S(þ)Ibuprofen–SARS-CoV-2 complexes, it was
decided to analyse the frustration patterns of the structures
obtained from the MD simulations. It has been demonstrated
that several functional aspects of proteins present enrichment
of highly frustrated interactions (Ferreiro et al., 2007, 2014;
Freiberger et al., 2019).
Therefore, local frustration was calculated and analysed
with the aim of better understanding the functional regions
of SARS-CoV-2 Mpro. In addition, due to the differences
found in the binding energies analysed in the previous stud-
ies it was of interest to detect differences in frustration under
the different simulated environments because they would be
directly affecting the protein–ligand interactions.
Figure 5. Hydrogen bond profiles of the SARS-CoV-2 Mpro complexes having with R()Ibuprofen (in red) and S(þ)Ibuprofen (in black) in different conditions.
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Figure 6 shown the frustration logo for each condition for
R()Ibuprofen–SARS-CoV-2 complex and S(þ)Ibuprofen–SARS-
CoV-2 complex in Figure S3, supplementary material. For both
complexes, the frustration patterns were very similar and had
highly frustrated residues in the three domains.
Domain I
In the frustration logos, there are residues that are conserved
(Information Content (IC) > 0.5) and highly frustrated in all
conditions for both complexes. In Domain I, these residues
are Asp33, Lys61 and Asn95. However, some residues are
frustrated only in R()Ibuprofen–SARS-CoV-2 complex (Figure
6), which are Aps34, Glu55, Asn63 and Lys88; nevertheless,
for S(þ)Ibuprofen–SARS-CoV-2 these residues are frustrated
only in some conditions (Figure S3, supplementary material).
In this domain is located the Loop Cys44-Pro52 which
could be regulating the access to the active site because the
most important sites for the biological function of SARS-CoV-
2 Mpro are located close to this loop (Bzowka et al., 2020).
We observed that some residues of this region do not con-
serve their frustration state.
Domain II
Some residues are highly frustrated and conserved in all con-
ditions for both complexes. These residues are Lys102,
Glu166, Asp176 and Tyr182. Whereas, some residues are frus-
trated only in S(þ)Ibuprofen–SARS-CoV-2 complex (Figure
S3), which are, Tyr118 and Pro132.
In this domain is located the Linker loop, it is a loop that
connects Domain II with Domain III (Bzowka et al., 2020). Both
complexes present in this loop some residues that change their
state of frustration in different conditions and some do not
conserve their state of frustration. Ala191 is conserved and frus-
trated in all conditions in R()Ibuprofen–SARS-CoV-2 complex;
Figure 6. Conservation of local frustration for R()Ibuprofen–SARS-CoV-2 complex for all conditions. For Domain I (in black square the loop C44-P5), Domain II (in
black square Linker Loop) and for Domain III. Marked with narrow residues that are highly frustrated and conserved (Information Content (IC) > 0.5) in all condi-
tions. In green minimally frustrated, in red highly frustrated and in grey neutral residues.
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although, this residue in S(þ)Ibuprofen–SARS-CoV-2 complex is
conserved and frustrated in all conditions except in condition 4.
Domain I and II
A recent study suggests that the residues Leu32, Asp33, Asp34,
Val35, Tyr37, Gln83, Lys88, Tyr101, Lys102, Phe103, Val104,
Arg105, Asp108, Phe159, Cys160, Asp176, Leu177 and Glu178
are located in Domain I and II and they could form an allosteric
site where the binding to them could affect the dimerization of
the protein (Panagiotopoulos et al., 2020). In our study, we
observe that some of these residues are highly frustrated in
both complexes and in all conditions, so we consider that these
residues would be involved in a biological function.
Domain III
In this domain, there are differences in the frustration of the resi-
dues for both complexes. Despite this, the residues Lys236,
Gln244, Lys269, Glu270 and Glu288 are conserved and frustrated
in both complexes and in all conditions. Asn203 is frustrated and
conserved only in R()Ibuprofen–SARS-CoV-2 complex. We
observe more frustrated residues in S(þ)Ibuprofen–SARS-CoV-2
complex than in R()Ibuprofen–SARS-CoV-2 complex. We sug-
gest that these differences in frustration are given by the chem-
ical entity of the S(þ)enantiomer; as it was mentioned, this
domain is implicated in dimerization so this enantiomer could be
affecting the stability of the dimer.
Contact level frustration
We analysed the frustration at the contact level (configurational
index) for Cys44-Pro52 and Linker Loop regions (see Tables S17
and S18, supplementary material) due to the two enantiomers
of Ibuprofen not only form hydrophobic and hydrogen bond
interactions with these regions (Figure S1) but also, they have
differences in the frustration state (Figure 6, S3).
Loop Cys44-Pro52
Table S17 shown the highly frustrated (IC > 0.5) and con-
served contacts (IC_Contact: number of structures in which
that contact is established > 0.5) of the loop Cys44-Pro52
for R()Ibuprofen–SARS-CoV-2 complex (red) and
S(þ)Ibuprofen–SARS-CoV-2 complex (black).
The R()Ibuprofen–SARS-CoV-2 Mpro complex shows
more frustrated interactions in condition 2 and 4. It is
observed that only in condition 2 for both complexes, the
residue of Pro52 is forming a highly frustrated contact with
Arg188, this residue is important for substrate binding and it
is located in the Linker loop.
Linker loop
Table S18 shown the highly frustrated (IC > 0.5) and con-
served contacts (IC_Contact > 0.5) of the Linker loop for
R()Ibuprofen–SARS-CoV-2 Mpro complex (red) and
S(þ)Ibuprofen–SARS-CoV-2 complex (black).
Different highly frustrated contacts were observed under dif-
ferent conditions. The R()Ibuprofen–SARS-CoV-2 Mpro
complex shows more frustrated interactions in condition 1 and
4. In the majority of the conditions, except condition 2, the
highly frustrated contact is between the residues that are form-
ing the Linker loop structure. As mentioned above, in condition
2, the contact Pro52-Arg188 is highly frustrated in both com-
plexes and Met165-Gln192 in S(þ)Ibuprofen–SARS-CoV-
2 complex.
Due to the highly frustrated interaction between Pro52-
Arg188 present in both complexes in condition 2, we sug-
gest that this contact could be provided by the concentra-
tion of NaCl and this could be contributing favourably to the
protein–ligand interaction.
Conclusions
From in silico analysis performed, we could predict the bind-
ing affinities and conformational stability of Ibuprofen enan-
tiomers with the main protease of SARS-CoV-2. We also
evaluated the influence of ionic strength (NaCl concentra-
tions) on the affinity and stability of the Ibuprofen–Mpro
complexes. The aim was to examine if this known and widely
used anti-inflammatory drug may be used in the treatment
against COVID-19 infection.
Our docking results showed that both ibuprofen enan-
tiomers it successfully docked against the inhibitor region of
the main protease of SARS-CoV-2 virus, with bindings ener-
getically favourable. Both interacting with catalytic residues,
the substrate-binding pocket and interacting with residues
involved in the dimerization process. Binding free energy cal-
culations using the MM-GBSA and MM-PBSA confirm the
affinity of these complexes. It also demonstrates that the
ionic strength (NaCl concentrations) modifies significantly
their binding affinities.
RMSD and RMSF parameters estimated from trajectories
generated by the MD simulations (120ns) reveal that these
complexes are conformational stable in all conditions analysed.
In this context, the binding energies analysis, the number of
hydrogen bonds along with the RMSD-RMSF results suggest
that the condition 2 (0.25 NaCl) bound more tightly the
Ibuprofen to the SARS-CoV-2 Mpro than the others conditions.
From the frustration analysis, we could characterize two
important regions (Cys44-Pro52 and Linker loop) of this protein
involved in the interaction with Ibuprofen. Also, we could find
that residues involved in the biological activity of the protein
are highly frustrated in all the conditions simulated.
We suggest that in condition 2, the NaCl concentration and
the ligand are affecting positively to Loop Cys44-Pro52 and
Linker loop structures benefiting protein–ligand interactions.
We conclude that besides the known anti-inflammatory
effects that help to reduce the harmful effects of inflamma-
tion on the host, Ibuprofen can provide an additional benefi-
cial therapeutic result. Considering that viral respiratory
infection therapy has three main purposes: (1) to reduce
symptoms; (2) to limit viral involvement of ear, sinus, bronchi
and lungs; and (3) to decrease viral replication and spread
of infection.
We propose that Ibuprofen may represent a potential
treatment option of COVID-19 by directly affecting the
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replication of the virus, further strengthening the concept of
drug repurposing. However, these results require further lab
experiments and clinical studies to be carried out to validate
its effectiveness. The differences in pharmacological activity
between the two isoforms need to be understood.
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